Ries Markus, Schaefer Ellen, Lührs Till, Mani Latha, Kuhn Jana, Vanier Marie T, Krummenauer Frank, Gal Andreas, Beck Michael, Mengel Eugen
Center for Lysosomal Storage Disorders, Children's Hospital, University of Mainz, Mainz, Germany.
J Inherit Metab Dis. 2006 Oct;29(5):647-52. doi: 10.1007/s10545-006-0363-3. Epub 2006 Jul 27.
Laboratory diagnosis of lysosomal storage disorders, especially sphingomyelinase deficiency (Niemann-Pick disease type A/B) and Niemann-Pick disease type C (NPC) can be challenging. We therefore aimed to analyse the feasibility of first-step screening with specific chitotriosidase cut-off values in children </= 10 years of age with visceral organomegaly (hepatomegaly, splenomegaly, or hepatosplenomegaly) in whom a storage disorder was suspected. We conducted a retrospective, cross-sectional, referral, single-centre study to assess diagnostic test properties in 106 individuals. Median chitotriosidase activity was 12 655 nmol/h per ml (interquartile range 4693-20982) in Gaucher disease (GD); 780 (465-1298) in SMD (sphingomyelinase deficiency); 925 (319-1215) in NPC and 50 (29-54) in patients with miscellaneous diseases. To restrict the differential diagnosis to GD, SMD or NPC, chitotriosidase activity above 200 nmol/h per ml had a sensitivity of 96%, specificity of 100%, positive predictive value (PPV) of 100%, and negative predictive value (NPV) of 95%. For GD alone, chitotriosidase activity above 4000 nmol/h per ml had a sensitivity of 77%, specificity of 100%, PPV of 100% and NPV of 92%. Of the 44 patients analysed, 4.5% were homozygous and 36.4% heterozygous for chitotriosidase gene duplication. Adjusting for the chitotriosidase genotype, chitotriosidase activities were higher in GD type III than in GD type I. We conclude that, in the above setting, the degree of elevation of chitotriosidase activity can be applied to increase the likelihood of GD, SMD, or NPC and guide the choice of the appropriate confirmatory assay.
溶酶体贮积症的实验室诊断,尤其是鞘磷脂酶缺乏症(A型/ B型尼曼-匹克病)和C型尼曼-匹克病(NPC)可能具有挑战性。因此,我们旨在分析对10岁及以下怀疑患有贮积症且有内脏器官肿大(肝肿大、脾肿大或肝脾肿大)的儿童,采用特定的壳三糖苷酶临界值进行初步筛查的可行性。我们进行了一项回顾性、横断面、转诊、单中心研究,以评估106名个体的诊断测试特性。戈谢病(GD)患者的壳三糖苷酶活性中位数为每毫升12655 nmol/h(四分位间距4693 - 20982);鞘磷脂酶缺乏症(SMD)患者为780(465 - 1298);NPC患者为925(319 - 1215);其他杂病患者为50(29 - 54)。为了将鉴别诊断局限于GD、SMD或NPC,壳三糖苷酶活性高于每毫升200 nmol/h时,敏感性为96%,特异性为100%,阳性预测值(PPV)为100%,阴性预测值(NPV)为95%。仅针对GD,壳三糖苷酶活性高于每毫升4000 nmol/h时,敏感性为77%,特异性为100%,PPV为100%,NPV为92%。在分析的44例患者中,4.5%为壳三糖苷酶基因重复的纯合子,36.4%为杂合子。校正壳三糖苷酶基因型后,Ⅲ型GD患者的壳三糖苷酶活性高于Ⅰ型GD患者。我们得出结论,在上述情况下,壳三糖苷酶活性的升高程度可用于增加GD、SMD或NPC的可能性,并指导选择合适的确诊检测方法。